FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study EB613 Phase 2 Data Demonstrating Consistent Efficacy across Younger Post-Menopausal Women with Osteoporosis and its Imp ...
Total Revenue of $12.4 Million Direct Operating Margin of 58%, a 7% Improvement over Prior Year Quarter LOS ANGELES, Nov. 14, 2025 /PRNewswire/ -- Cineverse Corp.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback